CNTO1959UCO3001: A Phase 2b/3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
CNTO1959UCO3001: A Phase 2b/3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with moderately to severely active ulcerative colitis (UC).
Inclusion Criteria:
Exclusion Criteria:
Caba, C1426ABP, Argentina
Ciudad de Buenos Aires, C1430EGF, Argentina
Campinas, 13060-904, Brazil
Salvador, 41500-300, Brazil
Sofia, 1784, Bulgaria
Shanghai, 200025, China
Hradec Kralova, 500 02, Czechia
Szeged, 6725, Hungary
Ehime, 790-0024, Japan
Fujiidera-shi, 583-0027, Japan
Fukuoka-ken, 802-0077, Japan
Hashima-gun, 501-6062, Japan
Hokkaido, 078 8510, Japan
Kumagaya-shi, 360-8567, Japan
Meguro Ku, 152 8902, Japan
Nishinomiya Shi, 663 8501, Japan
Shinjuku-ku, 169-0073, Japan
Sumida Ku, 130 8575, Japan
Kelantan, 16150, Malaysia
Nizhny Novgorod, 603140, Russia
Ivano-Frankivsk, 76008, Ukraine
Kharkiv, 61037, Ukraine
Kharkiv, 61039, Ukraine
Odesa, 65025, Ukraine
Sumy, 40022, Ukraine
Ternopil, 46002, Ukraine
Vinnytsia, 21018, Ukraine